Key result
Combining NT-proBNP >507 ng/L with hs-cTnT >99th percentile was associated with a 3-fold increased risk of cardiovascular mortality over 10 years (P<0.0001).
Why the study?
Does combining hs-cTnT and NT-proBNP measurements improve prognostic assessment for cardiovascular mortality in elderly patients with symptoms of heart failure?
Cohort (n=470)
No
Does combining hs-cTnT and NT-proBNP measurements improve prognostic assessment for cardiovascular mortality in elderly patients with symptoms of heart failure?
Hazard Ratio: 3
p-value: p=< 0.0001
Combining hs-cTnT and NT-proBNP measurements provides superior prognostic information for 10-year cardiovascular mortality in elderly patients with heart failure symptoms compared to using either biomarker alone.
No takes yet. Share an insight, caveat, or question.
May aid risk stratification in symptomatic elderly; hypothesis-generating before guiding therapy or changing practice.
Alehagen et al. (2010) conducted a cohort in symptoms of heart failure (n=470). Combined high-sensitivity cardiac troponin T (hs-cTnT) >99th percentile and NT-proBNP >507 ng/L vs. Either biomarker separately or neither elevated was evaluated on cardiovascular mortality (3-fold increased risk, p=< 0.0001). Combining NT-proBNP >507 ng/L with hs-cTnT >99th percentile was associated with a 3-fold increased risk of cardiovascular mortality over 10 years (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: